Serum Visfatin Increases With Progressive β-Cell Deterioration

• Published in: Diabetes (New York, N.Y.) Vol. 55; no. 10; pp. 2871 - 2875
• Main Authors: Lopez-Bermejo, Abel, Chico-Julia, Berta, Fernandez-Balsells, Merce, Recasens, Monica, Esteve, Eduardo, Casamitjana, Roser, Ricart, Wifredo, Fernandez-Real, Jose-Manuel
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.10.2006
• Subjects: Adult; Aged; Biological and medical sciences; Cross-Sectional Studies; Cytokines - blood; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - pathology; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - pathology; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Genetic aspects; Humans; Insulin - metabolism; Insulin Secretion; Insulin-Secreting Cells - pathology; Male; Medical sciences; Middle Aged; Nicotinamide Phosphoribosyltransferase; Plasma cells; Type 2 diabetes; Endocrinopathy; Serum; β Cell; Diabetes mellitus; Langerhans islet; Endocrine pancreas
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db06-0259

Serum Visfatin Increases With Progressive β-Cell Deterioration Abel López-Bermejo 1 2 , Berta Chico-Julià 1 2 , Mercè Fernàndez-Balsells 1 2 , Mònica Recasens 1 2 , Eduardo Esteve 1 2 , Roser Casamitjana 3 , Wifredo Ricart 1 2 and José-Manuel Fernández-Real 1 2 1 Diabetes, Endocrinology and Nutrition Unit, Dr. Josep Trueta Hospital, Girona, Spain 2 Girona Institute for Biomedical Research, Girona, Spain 3 Endocrine Laboratory, University Clinical Hospital, Barcelona, Spain Address correspondence and reprint requests to Abel López-Bermejo, MD, Unit of Diabetes, Endocrinology and Nutrition, Dr. Josep Trueta Hospital, Av. Francia s/n, 17007 Girona, Spain. E-mail: uden.alopez{at}htrueta.scs.es Abstract Visfatin has shown to be increased in type 2 diabetes but to be unrelated to insulin sensitivity. We hypothesized that visfatin is associated with insulin secretion in humans. To this aim, a cross-sectional study was conducted in 118 nondiabetic men and 64 (35 men and 29 women) type 2 diabetic patients. Type 1 diabetic patients with long-standing disease ( n = 58; 31 men and 27 women) were also studied. In nondiabetic subjects, circulating visfatin (enzyme immunoassay) was independently associated with insulin secretion (acute insulin response to glucose [AIRg] from intravenous glucose tolerance tests) but not with insulin sensitivity ( S i ) or other metabolic or anthropometric parameters, and AIRg alone explained 8% of visfatin variance (β = −0.29, P = 0.001). Circulating visfatin was increased in type 2 diabetes (mean 18 [95% CI 16–21] vs. 15 ng/ml [13–17] for type 2 diabetic and nondiabetic subjects, respectively; P = 0.017, adjusted for sex, age, and BMI), although this association was largely attenuated after accounting for HbA 1c (A1C). Finally, circulating visfatin was found to be increased in patients with long-standing type 1 diabetes, even after adjusting for A1C values (37 ng/ml [34–40]; P < 0.0001, adjusted for sex, age, BMI, and A1C compared with either type 2 diabetic or nondiabetic subjects). In summary, circulating visfatin is increased with progressive β-cell deterioration. The study of the regulation and role of visfatin in diabetes merits further consideration. AIRg, acute insulin response to glucose FSIGT, frequently sampled intravenous glucose tolerance test OGTT, oral glucose tolerance test Footnotes The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Accepted July 19, 2006. Received February 23, 2006. DIABETES